The lawsuit claims that the three drugmakers participated in pay-for-delay deals to prevent the release of a generic, cheaper version of the wakefulness drug Provigil.
The settlement resolves a class-action lawsuit brought by health plans and other indirect purchasers of Provigil.
Read the full report here.
More articles on pharmacy:
10 hospitals seeking pharmacy leadership
Patent protection clause is latest stumbling block for revised NAFTA
Dr. Reddy’s legal win expected to lower cost of opioid addiction treatment
